The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBA
Coherence Neuro
Developing implantable bioelectronic systems to record neural activity and advance adaptive cancer therapy.
What they do
Coherence Neuro is developing bioelectronic technology for cancer monitoring and treatment. Its $45 million funding round was co-led by Founders Fund and OpenAI Startup Fund. Co-founders Ben Woodington and Elise Jenkins serve as CEO and CTO, respectively. The investigational CIPHER System records and stimulates cortical activity in a first clinical study; it is not an approved cancer treatment. Electrical biomarkers and closed-loop cancer therapy remain under development. At least $45 million in funding is disclosed. Sources: https://www.coherenceneuro.com/article/inventing-cancer-therapy-that-learns and https://www.coherenceneuro.com/article/coherence-neuro-has-started-its-first-clinical-study
The record
- Vertical
- Oncology
- Sub-segment
- Bioelectronic oncology and neurotechnology
- Product type
- Device
- Stage
- Series A
- Headquarters
- San Francisco, CA, United States
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $45M raised
Notable investors: Founders Fund, OpenAI Startup Fund, Lux Capital, 8VC, Ahren Innovation Capital, Matthew MacDougall.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Skull as Therapeutic Infrastructure: How CraniUS and Chronic Convection Delivery Bypass the Blood-Brain Barrier
Dr. Dereck Mush, MD, MBA
The Curative Adjuvant Checkpoint Pivot: How Genentech's ATOMIC Approval Redefines Early GI Oncology Economics and Reflex Testing Infrastructure
Dr. Dereck Mush, MD, MBA
Dismantling the 25-Year R-CHOP Monopoly: Frontline Bispecifics and the Future of Lymphoma
Dr. Dereck Mush, MD, MBA